These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16723229)

  • 21. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
    Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
    Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.
    Gilmore JL; King BW; Harris C; Maduskuie T; Mercer SE; Liu RQ; Covington MB; Qian M; Ribadeneria MD; Vaddi K; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2006 May; 16(10):2699-704. PubMed ID: 16516466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
    Wu D; Gu Q; Zhao N; Xia F; Li Z
    J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
    Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
    J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.
    Xue CB; Chen XT; He X; Roderick J; Corbett RL; Ghavimi B; Liu RQ; Covington MB; Qian M; Ribadeneira MD; Vaddi K; Trzaskos J; Newton RC; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4453-9. PubMed ID: 15357971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reverse hydroxamate-based selective TACE inhibitors.
    Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
    Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
    Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
    Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
    Feng WF; Zhao YB; Huang W; Yang YZ
    J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
    Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
    SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
    Guo Z; Orth P; Wong SC; Lavey BJ; Shih NY; Niu X; Lundell DJ; Madison V; Kozlowski JA
    Bioorg Med Chem Lett; 2009 Jan; 19(1):54-7. PubMed ID: 19054672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.
    Zask A; Kaplan J; Du X; MacEwan G; Sandanayaka V; Eudy N; Levin J; Jin G; Xu J; Cummons T; Barone D; Ayral-Kaloustian S; Skotnicki J
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1641-5. PubMed ID: 15745814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.
    Chen XT; Ghavimi B; Corbett RL; Xue CB; Liu RQ; Covington MB; Qian M; Vaddi KG; Christ DD; Hartman KD; Ribadeneira MD; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1865-70. PubMed ID: 17276676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation.
    DasGupta S; Murumkar PR; Giridhar R; Yadav MR
    Bioorg Med Chem; 2009 May; 17(10):3604-17. PubMed ID: 19394232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel TACE inhibitors in drug discovery: a review of patented compounds.
    Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
    Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and SAR of hydantoin TACE inhibitors.
    Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.